The potential €100 million (US$114 million) deal disclosed Feb. 10 between infectious disease specialist Aicuris Anti-infective Cures AG and Hybridize Therapeutics for a BK virus therapy stimulated interest in the space, where a number of players are seeking a treatment. None exists today.
Infectious disease specialist Aicuris Anti-infective Cures AG has signed a worldwide license agreement worth up to €100 million (US$114 million) with Hybridize Therapeutics for a potential therapy to prevent BK virus (BKV) infections in immunocompromised patients.
